INVO vs. QNRX, IONM, STSS, GMVDF, TNON, AEMD, RSLS, DYNT, VERO, and TMDIF
Should you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include Quoin Pharmaceuticals (QNRX), Assure (IONM), Sharps Technology (STSS), G Medical Innovations (GMVDF), Tenon Medical (TNON), Aethlon Medical (AEMD), ReShape Lifesciences (RSLS), Dynatronics (DYNT), Venus Concept (VERO), and Titan Medical (TMDIF). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals (NASDAQ:QNRX) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Quoin Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 3.3% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, INVO Bioscience had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 3 mentions for INVO Bioscience and 0 mentions for Quoin Pharmaceuticals. INVO Bioscience's average media sentiment score of 1.31 beat Quoin Pharmaceuticals' score of 0.45 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.
INVO Bioscience received 2 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 55.56% of users gave Quoin Pharmaceuticals an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Quoin Pharmaceuticals' net margin of -459.42%. Quoin Pharmaceuticals' return on equity of 0.00% beat INVO Bioscience's return on equity.
Quoin Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 426.32%. Given INVO Bioscience's higher possible upside, research analysts clearly believe Quoin Pharmaceuticals is more favorable than INVO Bioscience.
INVO Bioscience has higher revenue and earnings than Quoin Pharmaceuticals.
Summary
Quoin Pharmaceuticals and INVO Bioscience tied by winning 7 of the 14 factors compared between the two stocks.
Get INVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INVO Bioscience Competitors List
Related Companies and Tools
